These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18363517)

  • 1. Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.
    Harrison M; Swanton C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):523-46. PubMed ID: 18363517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule dynamics as a target in oncology.
    Risinger AL; Giles FJ; Mooberry SL
    Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
    Fojo T; Menefee M
    Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
    Andreopoulou E; Muggia F
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epothilones in prostate cancer: review of clinical experience.
    Dawson NA
    Ann Oncol; 2007 Jul; 18 Suppl 5():v22-7. PubMed ID: 17656558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.
    Edelman MJ; Shvartsbeyn M
    Clin Lung Cancer; 2012 May; 13(3):171-80. PubMed ID: 22133291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epothilones: a novel class of non-taxane microtubule-stabilizing agents.
    Altaha R; Fojo T; Reed E; Abraham J
    Curr Pharm Des; 2002; 8(19):1707-12. PubMed ID: 12171542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
    Villanueva C; Dufresne A; Pivot X; Viel E
    Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ixabepilone, a novel epothilone analogue.
    Pivot X; Dufresne A; Villanueva C
    Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.